Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rapid switch from intravenous epoprostenol to intravenous Remodulin(Rm) (Treprostinil sodium) in patients with stable pulmonary arterial hypertension: safety, efficacy and treatment satisfaction.

Next Previous
Trial Profile

Rapid switch from intravenous epoprostenol to intravenous Remodulin(Rm) (Treprostinil sodium) in patients with stable pulmonary arterial hypertension: safety, efficacy and treatment satisfaction.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Pulmonary hypertension
  • Focus Therapeutic Use
  • Sponsors United Therapeutics Corporation

Most Recent Events

  • 24 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 24 Mar 2009 Actual patient number (10) added as reported by ClinicalTrials.gov.
  • 24 Mar 2009 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top